Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Webhead who wrote (7578)	9/16/1999 9:00:00 PM
From: BlueCrab	Respond to of 8116

Ed, and anyone else who may be reading the CYTO thread, here is what Dr. Joe had to say about it: ``AxCell will begin discussions immediately with potential early subscribers. This program will give pharmaceutical organizations early access to this valuable data,' commented H. Joseph Reiser, Ph.D., Cytogen's President and Chief Executive Officer. ``While AxCell will be researching the entire proteome in creation of the database, the initial direction will be influenced by this select group of early subscribers,' added Dr. Reiser. After watching the good Dr. Joe and listening to his statements very carefully, we at the YAHOO thread kind of think that: - "Immediately" means "For a while now", and - "...influenced by this select group of early subscribers" means it's a done deal. I think we're on the right road.